Through its Discovering New Therapeutic Uses for Existing Molecules (New Therapeutic Uses) program, NCATS aims to improve the process of developing new treatments and cures for disease by finding new uses for existing therapies that already have cleared several key steps along the development path. Learn more about New Therapeutic Uses.
-
Research
-
Discovering New Therapeutic Uses for Existing Molecules
Drug Development Collaboratory (UG3/UH3 Clinical Trial Required)
This funding opportunity announcement supports intramural-extramural collaborations on late-stage translational science projects between NCATS Therapeutic Development Branch and extramural researchers.
Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required)
This urgent funding opportunity announcement invites applications to repurpose existing therapeutic agents to treat COVID-19 sequelae and associated complications that result from SARS-CoV-2 infections.
About New Therapeutic UsesRead more about the New Therapeutic Uses program and its progress.
New Therapeutic Uses Funding InformationFind out how to apply for New Therapeutic Uses funding.
Read more about the New Therapeutic Uses program and its progress.
Work with Us
Learn more about how you can access funding and collaborate with the New Therapeutic Uses program.
New Therapeutic Uses Facts
Therapeutic development is a costly, complex and time consuming process. The average length of time from target discovery to approval of a new drug is about 14 years. The failure rate during this process exceeds 95 percent, and the cost per successful drug can be $1 billion or more. The high therapeutic development failure rate means there are many existing, partially developed therapeutic candidates that could be repurposed for use in new disease indications.Learn more about the New Therapeutic Uses program through the fact sheet (PDF - 395KB).
NCATS Programs & Initiatives
-
